Identification of Biomarkers in Follicular Lymphoma
- Correlate gene expression profiles with progression-free survival (PFS) of patients
with stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine,
and prednisone with or without rituximab on clinical trial E-1496.
- Determine if immunoglobulin Fc-gamma receptor polymorphisms are predictive of PFS in
- Assess the significance of the microenvironment by constructing tissue microarrays of
follicular lymphoma and immunostaining with relevant biomarkers.
- Correlate relevant biomarkers with clinical features, response, and PFS.
OUTLINE: This is a multicenter study.
Tissue samples are analyzed by gene expression profiling, microarrays to predict gene
expression, immunohistochemistry, and immunoglobulin Fc-gamma receptor polymorphism analysis
for biological markers.
PROJECTED ACCRUAL: A total of 175 samples will be accrued for this study.
Correlation of gene expression profiles with progression-free survival (PFS)
Randall D. Gascoyne, MD
British Columbia Cancer Agency
United States: Federal Government